Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

Journal of Infectious Diseases

Volumn 181, Issue 3, 2000, Pages 1129-1132

  Glück, Reinhard ^a   Mischler, Robert ^a   Durrer, Peter ^a   Fürer, Emil ^a   Lang, Alois B ^a   Herzog, Christian ^a   Cryz Jr , Stanley J ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; INFLUENZA VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHINORRHEA; SEROCONVERSION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; BACTERIAL TOXINS; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; MIDDLE AGED;

EID: 0034072432     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315337     Document Type: Article

References (16)

1. 1. Michalek SM, Eldridge JH, Curtiss ILR, Rosenthal KL. Antigen delivery systems: new approaches to mucosal immunization. In: Ogra PL, McGhee SR, Mestecky J, eds. Handbook of mucosal immunology. San Diego: Academic Press, 1994:373-90.
2. 2. Tamura SI, Yajima A, Hatori, et al. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection. Vaccine 1997;15:1784-90.
3. 3. Tamura SI, Asanuma H, Tomita T, et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 1994;12:1083-9.
4. 4. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992;22:2277-81.
5. 5. Douce G. Turcotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995;92:1644-8.
6. 6. Hashigucci K, Ogawa H, Ishidate T, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 1996;14:113-9.
7. 7. Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344:160-3.
8. 8. Conne P, Gauthey L, Vernet P, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997;15:1675-9.
9. 9. Gluck U, Gebbers JO, Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J Virol 1999;73:7780-6.
10. 10. Uesaka Y, Otsuka Y, Lin Z, et al. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose. Microb Pathog 1994;16:71-6.
11. 11. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405-12.
12. 12. Giannasca PJ, Boden JA, Monath TP. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect Immun 1997; 65:4288-98.
13. 13. Tacket CO, Levine MM. Live oral vaccines and subunit (purified fimbriae and toxin subunit) vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New generation vaccines. 2d ed. New York: Marcel Dekker, 1997:875-83.
14. 14. de Haan L, Holtrop M, Verweij WR, Agsteribbe E, Wilschut J. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit. Vaccine 1996;14:260-6.
15. 15. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993;13:2105-11.
16. 16. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R Liss, 1986:155-68.